N4 Pharma PLC Nuvec licence extension (0355L)
20 Diciembre 2018 - 1:00AM
UK Regulatory
TIDMN4P
RNS Number : 0355L
N4 Pharma PLC
20 December 2018
20 December 2018
N4 Pharma Plc
("N4 Pharma" or the "Company")
Nuvec(R) licence extension
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing a novel delivery system for vaccines and cancer
treatments, today announces that it has extended the terms of its
licence agreement with UniQuest Pty Ltd ("UNIQUEST"), a University
of Queensland, Australia, company, for the exploitation of its
novel delivery system Nuvec(R) (the "Licence Agreement").
Previously, the Company had a licence to pursue the use of
nucleic acids in all human therapeutic treatments, with an option
to extend its licence to additional fields such as animal vaccines,
peptides and small molecules. Under the extended terms of the
Licence Agreement, the Company now has an exclusive global licence
for the commercialisation of Nuvec(R) in all these areas, as well
as other possible commercial applications, such as dual therapy
cancer treatments. The Company has subsequently licensed back to
UNIQUEST certain defined fields which the Company does not consider
relevant to the Company's targeted applications, but in which
UNIQUEST is intending to carry out research.
The provisions regarding the payment of royalties by the Company
to UNIQUEST remain unchanged from the original licence
agreement.
The Nuvec(R) particles have a hollow mesoporous structure with a
spiky external structure. The pores are not needed for the
transfection of DNA and RNA since the DNA and RNA is trapped within
the spikes of the Nuvec(R) structure. Under the Licence Agreement,
the Company is now able to investigate developing products loaded
with small molecules, that can enter into the hollow cavity of the
Nuvec(R) particles through the pores whilst simultaneously trapping
the DNA or RNA in the spikes. Combining small molecules, such as
chemotherapeutic payloads or cancer imaging agents, with DNA or RNA
could enable the Nuvec(R) particles to deliver both elements
directly into cancerous tumours, potentially creating a dual
therapy approach to cancer treatments.
Further novel uses of Nuvec(R) particles, such as direct loading
of small molecules into the core without adding DNA or RNA in the
spikes, could also potentially be developed as the unique spiky
structure of the particle in this instance can lead to good
adhesion and sustained compound release.
Nigel Theobald, CEO of N4 Pharma commented:
"With the extension of this Licence Agreement with UNIQUEST we
are now able to further enter into the ever growing field of cancer
treatment development by researching this new dual therapy approach
to the treatment of cancerous tumours through combining small
molecules with DNA and RNA to our Nuvec(R) particles. We can also
investigate the unique structure of Nuvec(R) for the improved
delivery of traditional small molecules, an area where existing
nanoparticles are already widely used.
"The extension of the Licence Agreement allows for many new
potential applications to be developed and we will be updating the
market on our plans in these areas in due course."
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Alma PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Alma PR
Josh Royston Tel: +44(0)778 090 1979
Robyn Fisher Tel: +44(0)754 070 6191
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
Nuvec(R) has already shown to be capable of loading and
delivering mRNA and pDNA into cells to the required level needed to
generate an immune response capable of strong antibody
production.
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGGGCUPUPRGMB
(END) Dow Jones Newswires
December 20, 2018 02:00 ET (07:00 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024